A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

Based largely on Cobenfy’s promise, Bristol Myers Squibb paid $14 billion to acquire the company that developed the drug, ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

Roche's oral anti-obesity candidate outperformed a similar candidate from Viking Therapeutics in terms of efficacy. Viking Therapeutics' oral anti-obesity candidate appears much easier to tolerate ...

Actress Karuna Pandey, known for her role in Pushpa Impossible, shares her journey from learning Bharatnatyam and Kathak to pursuing a degree in Performing Arts. Despite the pressures of social ...

BMS declined to comment on this story or on Terran’s development of its own prodrug formulation. However, Karuna Therapeutics – the original makers of KarXT, had previously discussed the importance of ...

The revenue for KarXT is expected to reach an annual total of $2.81 bn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...